JPH0393723A - Remedy for skin disease and production thereof - Google Patents

Abstract

PURPOSE:To obtain a remedy for skin disease having effectively inhibitory effects on growth of not only pathogenic fungi but also bacteria such as Staphylococcus aureus and Pseudomonas aeruginosa, comprising a fermentation product of a mixture of ground root of Rumex Acetosa L. and acetic acid. CONSTITUTION:Root of Rumex Acetosa L., a polygonaceous plant, is sufficiently ground in the presence of 5-15wt.% aqueous solution of acetic acid. The prepared ground substance is placed in a dark place at least for two months, maintained at 20-35 deg.C, fermented, solid substances of admixture is separated and removed by centrifugal separation or filtration to give a remedy for skin disease comprising a transparent liquid. The remedy effects prevents growth of fungi belonging to the genus Trichophyton and Microsporum, fungi causing latent mycotic infection and has extremely high antifungal activity especially against the latter.

Description

DETAILED DESCRIPTION OF THE INVENTION Field of Industrial Application The present invention relates to a novel therapeutic agent for skin diseases and a method for producing the same. More specifically, the present invention relates to the genus Trichophyton and Microsporum microspores.
Fermented sorrel root useful for superficial mycoses caused by pathogenic Soda in horses, etc., and skin diseases caused by bacteria such as Staphylococcus aureus, Sarratia spp., and Bacillus aeruginosa. The present invention relates to a skin disease treatment consisting of natural ingredients and a method for efficiently producing the same.

Conventional Techniques Mycosis is a disease caused by fungi, and can be clinically divided into superficial mycoses and deep mycoses. In cases of superficial maniasis, so-called water beetles such as sweaty white skin and gongkan white mania, etc. 1 (Tamushi), Kosui Kobatsuji f/I
These include those caused by autochthonous fungi and microsporum bacteria such as C. nigra, and those caused by the genus Candida, and are mainly treated with external preparations.

On the other hand, deep mycoses affect the deep skin, subcutaneous tissues, internal organs, bones, etc., such as pulmonary aspergillosis, pulmonary candidiasis, chromomycosis, suborotrichosis,
These include nocardiosis, and are mainly treated by systemic administration of drugs.

Conventionally, for the former skin disease caused by superficial mycosis, treatments such as undecylenic acid, imidazole anti-seedling agents such as clotrimazole, miconazole nitrate, econazole nitrate, and isoconazole nitrate, or the antibiotic tricomycin have been used. It is used. However, the efficacy of these drugs is not necessarily fully satisfactory, and there has been a strong demand for the development of a new skin treatment agent that effectively acts on superficial fibrosis.

On the other hand, in addition to the above-mentioned pathogenic sodium soda, it is also known that some fine soda can cause skin diseases. For example, Staphylococcus aureus
s aureus, S. aureus) is resident in the skin and mucous membranes of the human body, and is known to often cause purulent skin diseases.
Bacterium aeruginosa) lives in our environment and is normally a harmless bacteria, but it is not initially susceptible to many disinfectants and antibiotics, and sometimes causes so-called sun-baked infections and chlorination. May cause illness.

Therefore, a drug that effectively inhibits the growth of these bacteria as well as the above-mentioned pathogenic fungi is extremely useful as a therapeutic agent for skin diseases.

Problems to be Solved by the Invention Under these circumstances, the present invention is effective against superficial mycoses caused by pathogenic fungi, and is effective against Staphylococcus aureus, Serratia sp., Aeruginosa bacterium, etc. This invention was made with the aim of providing a new therapeutic agent for skin diseases that is also effective against skin diseases caused by bacteria.

Means for Solving the Problems The present inventor has conducted intensive research to develop a novel skin disease treatment agent having the above-mentioned properties. Focusing on the roots of sorrel, a plant belonging to the Polygonaceae family, the fermentation product of a mixture of ground sorrel roots and acetic acid was found to be effective against pathogenic fungi such as Trichophyton and Microsporum, as well as Staphylococcus aureus and Serratia spp. The inventors have discovered that scales effectively inhibit the growth of microorganisms such as Aeruginosa bacteria, and have completed the present invention based on this knowledge.

That is, the present invention provides a therapeutic agent for skin diseases made from a fermentation product of a mixture of ground sorrel root and acetic acid.

According to the present invention, the skin disease therapeutic agent is obtained by grinding sorrel roots in the presence of an acetic acid aqueous solution having a concentration of 5 to 15% by weight, and storing the ground product at 20 to 35°C in the dark for at least 2 months.
It can be produced by fermenting while maintaining the temperature at , and then separating and removing the solid content from the fermented product.

The present invention will be explained in detail below.

In the skin disease treatment agent of the present invention, sorrel root is used as a raw material. This sorrel is a perennial plant of the Polygonaceae family, and is widely distributed throughout the northern hemisphere. It is often found in fields, banks, roadsides, and rice field fields, and its grated root has been used as an external preparation to treat parasitic skin diseases such as tinnitus and keratin.

In the present invention, there is no particular restriction on the production area of the sorrel, and sorrel from any production area can be used.

Next, the method for producing the therapeutic agent for skin diseases of the present invention will be described. First, sorrel root is sufficiently ground in the presence of an acetic acid aqueous solution having a concentration of 5 to 15% by weight using a known grinder such as a mixer. There is no particular limit to the amount of acetic acid aqueous solution used at this time, but it is usually 1 to 20% per sorrel root.
It is used at a ratio of twice the weight.

The thus obtained ground product is then fermented by maintaining it in the dark at a temperature in the range of 20-35°C for at least 2 months, and then the solid content of impurities is removed from the fermentation product by centrifugation. By separating and removing by means such as separation or filtration, the therapeutic agent for skin diseases of the present invention consisting of a transparent liquid can be obtained.

The antibacterial activity against fungi and bacteria of the skin disease therapeutic agent of the present invention obtained in this way is determined by, for example, the minimum inhibitory concentration (minimum inhibitory concentration) of the Japanese Society of Chemotherapy.
ry concentration% MIC) can be determined by measuring MIG by an agar plate dilution method according to a standard measurement method.

According to the measurement of this MIC, the skin disease treatment agent effectively inhibits the growth of Trichophyton spp. and Microsporum spp., which are the causative fungi of superficial mycoses, and has particularly high antibacterial activity against Microsporum spp. In addition, it was confirmed that among sodium soda, there is almost no antibacterial activity against Aspergillus genus bacteria, which are not the causative fungi of superficial mycosis.

Therefore, the therapeutic agent for skin diseases is effective in treating superficial mycoses caused by Trichophyton and Microsporum spp., such as skin diseases caused by water beetles, ringworms, kidney beetles, and the like.

Furthermore, it was confirmed that the therapeutic agent for skin diseases of the present invention effectively inhibits the growth of seedlings of Staphylococcus aureus, Serratia sp., and Aeruginosa.

Staphylococcus aureus resides constantly in the skin and mucous membranes of the human body, and is also the cause of purulent diseases. Therefore, when a mixed infection with the above-mentioned pathogenic fungi occurs, the therapeutic agent for skin diseases of the present invention can be used. seems to be particularly effective.

In addition, the Serratia genus bacteria and the Serratia sp. The skin disease therapeutic agent of the present invention is also effective against these diseases.

There is no particular restriction on the formulation form of the skin disease therapeutic agent of the present invention, and it may be in any form that has been conventionally used as a skin disease therapeutic agent, such as lotion, liquid, cream, ointment, spray, etc. I can do it.

For example, the skin disease treatment agent may be used by incorporating it into a cream consisting of an aqueous emulsion of polyethylene glycol or liquid paraffin, or a white wax or white liquid paraffin base and stabilizers and preservatives used as necessary. It may also be used by containing it in an ointment consisting of.

Effects of the Invention The skin disease therapeutic agent of the present invention is a novel product consisting of a fermentation product of a mixture of ground sorrel root and acetic acid, and is a novel product that is composed of a fermentation product of a mixture of ground sorrel root and acetic acid. It is extremely useful for treating skin diseases caused by bacteria such as Staphylococcus aureus, Serratia sp.

Examples Next, the present invention will be explained in more detail with reference to examples.
The present invention is not limited in any way by these examples.

Example 1 Small piece of root of sorrel (collected on the west coast of Lake Biwa, Shiga Prefecture) 3009
After putting it in a mixer with edible vinegar lQ and grinding for 5 minutes, the ground product was stored in a dark place at 25-30℃ for 3 months.
It was kept and fermented. Next, this fermentation product was filtered to separate and remove solid contaminants to obtain a light brown transparent liquid fermentation product.

Example 2 The antibacterial activity of the fermented product obtained in Example 1 against various types of sodium soda was determined by measuring MIG using the agar plate dilution method.

As test fungi, Trichophyton mentagroph
ytes), Microsporum canis (Microsp
orum canis), Microsporum gypseum and Aspergillus fumigatus.
migatus), and as a double layer, Saburo・
Glucose agar base (Sabouraud's glue)
cose agar) and Sabo Broth (Sabo Broth)
It was carried out using uraud's broth).

A 2-fold serial dilution of the fermentation product obtained in Example 1 was made using Sabouraud broth, and further diluted from 2-fold to 128-fold to prepare diluted solutions of various concentrations.

Next, the above diluted fermentation product was dispensed into a Petri dish in 2 mQ portions starting from the lowest concentration, and as a control, 2 m+ of Sabouraud broth, which was used for dilution instead of the diluted liquid, was placed in a Petri dish.
2 was dispensed. Next, 18+ ml of Sabouraud glucose agar medium previously maintained at 45 to 50° C. was poured into each petri dish, thoroughly mixed with the fermentation product dilution or broth, and solidified. The diluted fermentation product was thereby further diluted by 10 times.

Next, one set of Petri dishes containing each fermentation product concentration and one Petri dish containing no fermentation product were inoculated with the test bacteria Pros culture solution by spotting them at 6 spots on the medium, and kept at 25℃ for 3 weeks. Culture was carried out, and the presence or absence of proliferation of seedlings was visually observed every day after 3 days, and the MIC of each sample solution was measured to determine antibacterial activity. The results are shown in Table I.

From Table 1, the MIC for tricho7iton is 2
0 times diluted concentration and 2 times diluted concentration for microsporum.
It can be seen that the growth of Soda was inhibited up to a 40-fold dilution concentration after 3 weeks of culture for both Soda.

On the other hand, in the case of Aspergillus 7migatus, bacterial growth was already observed after 3 days of culture, and after one week, even in a Petri dish containing a 10-fold dilution of the most concentrated stock solution, colonies had spread to the double base metal body. observed. Therefore, it can be seen that no antibacterial activity against Aspergillus bacteria was observed.

Example 3 The antibacterial activity of the fermented raw material obtained in Example 1 against various types of fine soda was determined by measuring MIG using the agar plate dilution method.

Staphylococcus aureus (S.
taphylococcus aureus) 209
- Ps Escherichia coli
coli) 0111: B4% Serratia marcescens and Pseudomonas aeruginosa
Asaeruginosa) and Hl agar (heart infusion agar) and Hl gloss (formerly broth) were used as the medium.

A 2-fold serial dilution of the fermentation product obtained in Example 1 was made using H[broth] and further diluted from 2-fold to 128-fold,
Dilutions of each concentration were prepared.

Next, the above diluted fermented product liquid was dispensed into a petri dish, starting from the one with the lowest concentration (2i), and as a control, old broth 2IIIQ, which was used for dilution instead of the diluted liquid, was dispensed into the petri dish. Next, H!Agar medium 18+1112, which had been maintained at 45-50°C in advance, was poured into each petri dish, mixed well with the fermentation product dilution solution or broth, and solidified. It will be diluted twice.

Next, one set of Petri dishes containing each fermentation product concentration and one Petri dish containing no fermentation product was added, and one drop of the test bacteria broth culture was dropped onto the medium, and spread with a conlage rod to inoculate them. Cultivate at 37°C for 72 hours and check for bacterial growth.
Antibacterial activity was determined by visual observation at 4 hours, 48 hours, 72 hours, and 1 week, and the MIC of each sample solution was measured.

So The results are shown in Table 2.

From Table 2, for Sta. 7 Irococcus aureus and Pseudomonas aeruginosa, at a 40-fold diluted concentration, bacterial growth was inhibited for up to 48 hours after inoculation, but bacterial growth was observed 72 hours later. It can also be seen that at a 20-fold diluted concentration, bacterial growth is inhibited even after one week has passed.

Furthermore, for Escherichia coli and Serratia marcescens, the MIC was 20 times diluted to 1 [degrees], indicating that the growth of the bacteria was inhibited even after one week had passed at this concentration.

Claims (1)

[Claims] 1. A therapeutic agent for skin diseases comprising a fermentation product of a mixture of ground sorrel root and acetic acid. 2 Sorrel roots are ground in the presence of an acetic acid aqueous solution with a concentration of 5 to 15% by weight, and the ground product is fermented by keeping it in the dark at a temperature of 20 to 35°C for at least 2 months, and then
A method for producing a skin disease therapeutic agent, which comprises separating and removing solid content from this fermentation product.